Our Company

1-2 of 2

An actuarial approach to the incremental cost of Hepatitis C in the absence of curative treatments24 September 2015 - By Andrew Bochner and Bruce S. Pyenson and Ryan Cannon - Article

HCV is the leading cause of both liver-related deaths and liver transplants in the United States. The high cost of new antiviral medicines has sparked debate over the cost of treating HCV, and some payers are seeking ways to minimize their spending on these medicines.

Aging will affect Medicare’s Hepatitis C mortality and cost16 July 2015 - By Bruce S. Pyenson and Gabriela Dieguez and Ryan Cannon - Article

This paper examines the mortality and cost dynamics affecting Medicare as the majority of Hepatitis C Virus (HCV)-infected people age into Medicare.

  • Work at Milliman

    • “I was offered a chance to come in, shake things up, create something."
    Work at Milliman